Immunic, Inc. (IMUX): R&D Expense
$81.98M
Year ended 2025-12-31
$90.64M
Trailing 12 months to 2026-06-30
+4.8%
3-year compound annual growth
+16.2%
5-year compound annual growth
+7.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $81.98M | +2.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $80.05M | -3.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $83.22M | +16.8% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $71.25M | +16.6% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $61.12M | +58.2% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $38.64M | +71.6% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $22.51M | +134.6% | 2021-02-26, From 2019-01-01 |
| 2018-12-31 | $9.60M | -75.6% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $39.34M | +30.9% | 2019-03-04, From 2017-01-01 |
| 2016-12-31 | $30.05M | -24.5% | 2019-03-04, From 2016-01-01 |
| 2015-12-31 | $39.77M | +0.7% | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | $39.48M | +81.2% | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | $21.79M | +327.4% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $5.10M | n/a | 2015-03-20, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Immunic, Inc. (IMUX) | 2025-12-31 | $81.98M | +2.4% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $11.03M | -22.6% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $10.78M | +37.5% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $10.21M | -5.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $24.90M | -26.0% |
Compare IMUX, RNTX, KPRX, HCWB side by side · Screen every company in Pharmaceutical Preparations ↗